Key result
The use of the BpTRU automated blood pressure device significantly increased the likelihood of therapeutic changes in hypertensive kidney transplant recipients compared to historic controls (OR 2.12).
Why the study?
Does the use of an automated blood pressure device (BpTRU) increase therapeutic changes in hypertensive kidney transplant recipients?
Population
244 adult kidney alone or combined kidney-pancreas transplant recipients with systolic blood pressure ≥ 130…
Comparison
Blood pressure measurement using an automated… vs Historical control group measured with the…
Design
Cohort
Authors
Loading...
May support automated BP monitoring to guide therapy in kidney transplant recipients; hypothesis-generating pending randomized trials.
Cohort (n=244)
No
Does the use of an automated blood pressure device (BpTRU) increase therapeutic changes in hypertensive kidney transplant recipients?
Odds Ratio: 2.12 (95% CI 1.72–3.83)
Absolute Event Rate: 56% vs 36%
p-value: p=0.013
The implementation of an automated blood pressure measurement device in a kidney transplant clinic significantly increased the rate of therapeutic changes for hypertensive patients, thereby reducing clinical inertia.
Kiberd et al. (2007) conducted a cohort in Hypertension in kidney transplant recipients (n=244). BpTRU automated blood pressure device vs. Historic controls (aneroid sphygmomanometer) was evaluated on Change in antihypertensive therapy (newly added medication, increased dose, or reduced immunosuppression) (OR 2.12, 95% CI 1.72-3.83, p=0.013). The use of the BpTRU automated blood pressure device significantly increased the likelihood of therapeutic changes in hypertensive kidney transplant recipients compared to historic controls (OR 2.12).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: